(1,4-dioxan-2-yl)methyl methanesulfonate | 151720-03-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 英文名称: (1,4-dioxan-2-yl)methyl methanesulfonate
• 英文别名: 1,4-Dioxan-2-ylmethyl methanesulfonate
• CAS: 151720-03-5
• 化学式: C₆H₁₂O₅S
• 分子量: 196.224
• InChiKey: ZHPDCKBIEGGTKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  70.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (1,4-dioxan-2-yl)methyl methanesulfonate 、 tert-butyl (7-(2,6-dimethoxy-4-(methoxymethyl)phenyl)-2-(methylthio)pyrazolo[1,5-a]pyridin-3-yl)carbamate 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  Synthesis and Structure–Activity Relationships of Pyrazolo[1,5-a]pyridine Derivatives: Potent and Orally Active Antagonists of Corticotropin-Releasing Factor 1 Receptor

  摘要：

  Design, synthesis, and structure activity relationships of a series of 3-dialkylamino-7-phenyl pyrazolo[1,5-a]pyridines (I) as selective antagonists of the corticotropin-releasing factor 1 (CRF1) receptor are described. The most prominent compound to emerge from this work, 46 (E2508), exhibits potent in vitro activity, excellent drug-like properties, and robust oral efficacy in animal models of stress-related disorders. It has advanced into clinical trials.

  DOI：

  10.1021/jm300259r

文献信息

• Tyrosine kinase inhibitors
  申请人：Avalle Paolo

  公开号：US20090182002A1

  公开（公告）日：2009-07-16

  This invention relates to salt forms of the compound N-[(2R)-1,4-dioxan-2-ylmethyl]-N-methyl-N′-[3-(1-methyl- 1 H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]sulfamide, an inhibitor of tyrosine kinases, in particular the receptor tyrosine kinase MET, that are useful in the treatment of cellular proliferative diseases, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation. in particular, the invention relates to the sodium salt of N-[(2R)-1,4-dioxan-2-ylmethyl]-N-methyl-N′-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]sulfamide.

  这项发明涉及化合物N-[(2R)-1,4-二氧杂环戊烷-2-基甲基]-N-甲基-N′-[3-(1-甲基-1H-吡唑-4-基)-5-氧代-5H-苯并[4,5]环庚[1,2-b]吡啶-7-基]磺酰胺的盐形式，该化合物是一种酪氨酸激酶抑制剂，特别是受体酪氨酸激酶MET的抑制剂，对于治疗细胞增殖性疾病，例如癌症、增生、再狭窄、心肌肥大、免疫紊乱和炎症等疾病具有用处。特别是，该发明涉及N-[(2R)-1,4-二氧杂环戊烷-2-基甲基]-N-甲基-N′-[3-(1-甲基-1H-吡唑-4-基)-5-氧代-5H-苯并[4,5]环庚[1,2-b]吡啶-7-基]磺酰胺的钠盐。
• FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS
  申请人：Novartis AG

  公开号：US20180312507A1

  公开（公告）日：2018-11-01

  The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

  这项发明提供了如下所述的化合物的化学式(I)，以及药用盐、含有这些化合物的药物组合物，以及使用这些化合物、盐和组合物治疗病毒感染，特别是由乙型肝炎病毒引起的感染，并减少与HBV相关的严重病情发生的方法。
• [EN] MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DE MCL-1 MACROCYCLIQUE ET PROCÉDÉS D'UTILISATION
  申请人：ABBVIE INC

  公开号：WO2019035927A1

  公开（公告）日：2019-02-21

  The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

  本公开提供了Formula (I)中A2、A3、A4、A6、A7、A8、A15、RA、R5、R9、R10A、R10B、R11、R12、R13、R14、R16、W、X和Y的化合物，这些化合物的任何值均在规范中定义，并且其药学上可接受的盐，可用作治疗疾病和病况，包括癌症的药物。还提供了包含Formula (I)中化合物的药物组合物。
• INHIBITORS OF BETA-SECRETASE
  申请人：Bukhtiyarov Yuri

  公开号：US20140057927A1

  公开（公告）日：2014-02-27

  The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates.

  本发明涉及螺环式酰基胍和其作为β-分泌酶（BACE1）活性抑制剂的用途，包含同样成分的药物组合物，以及将其用作治疗神经退行性疾病、认知衰退、认知障碍、痴呆和由β-淀粉样蛋白聚集产生的疾病的治疗剂的方法。
• [EN] 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES<br/>[FR] DÉRIVÉS DE 1H-PYRROLO[2,3-B]PYRIDINE COMME INHIBITEURS BCL-2 POUR LE TRAITEMENT DES MALADIES NÉOPLASIQUES ET AUTO-IMMUNES
  申请人：GUANGZHOU LUPENG PHARMACEUTICAL COMPANY LTD

  公开号：WO2021133817A1

  公开（公告）日：2021-07-01

  The present invention relates to lH-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for treating neoplastic, autoimmune or neurodegenerative diseases. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 162 to 233; examples 1 to 8; table; compound examples cpd-1 to cpd-135; biological examples 1 to 4).

  本发明涉及LH-吡咯并[2,3-b]吡啶衍生物及相关化合物作为BCL-2抑制剂，用于治疗肿瘤、自身免疫或神经退行性疾病。本说明书披露了示例化合物的合成和表征，以及其药理学数据（例如第162至233页；示例1至8；表格；化合物示例cpd-1至cpd-135；生物学示例1至4）。